Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Perrigo (PRGO) Stock Undervalued Right Now?

DUBLIN , May 24, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it is scheduled to host 1x1 investor meetings at the Oppenheimer 23rd Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 13 th.   About Perrigo   Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference

In 2021, I hoped and anticipated that Perrigo Company plc was leaving its turbulent past behind. The company resolved its issues around its tax situation, but then announced a rather expensive deal as well.

Perrigo Company: Still Not Getting There

DUBLIN , May 16, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Nicotine Coated Mint Lozenges, 2 mg and 4 mg over-the-counter (OTC). This product will be marketed under retailer's store brand labels as a comparable offering to Nicorette® Coated Ice Mint Lozenge.

PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE

Certain lots of Perrigo's Gerber Good Start SoothePro powdered infant formula had been recalled in March out of an abundance of caution due to the potential presence of cronobacter sakazakii.

Gerber baby formula with potential bacteria was shipped to stores after recall: feds

ImmunityBio

Immunitybio Inc (NASDAQ:IBRX) stock is crumbling today, down 52.1% at $2.98 at last glance, and earlier as low as $2.45, after the U.S. Food and Drug Administration (FDA) declined to approve its bladder cancer therapy.

2 Pharma Stocks in Focus on FDA Buzz

U.S. Food and Drug Administration advisory committees meeting jointly on Wednesday voted unanimously that the benefits of making Opill, a birth control pill, available for use without a prescription would outweigh the risks, drugmaker Perrigo Co. PLC PRGO said in a release. The joint committee's vote is not binding, but the FDA often follows advisory committee recommendations.

FDA committee votes in favor of over-the-counter birth control pill

DUBLIN , May 10, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill®, a progestin-only daily oral contraceptive, available for over-the-counter (OTC) use outweighs the risks. The joint committee's vote, while not binding, will be considered by the FDA when making its final decision regarding the potential approval of Opill® for OTC use, which is expected later this year.

FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use

Perrigo Company plc. (NYSE:PRGO ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Murray Kessler - President, Chief Executive Officer Eduardo Bezerra - Executive Vice President, Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Genuity Ethan Brown - JPMorgan Daniel Biolsi - Hedgeye Operator Good morning and welcome to the Perrigo First Quarter 2023 Financial Results Conference Call.

Perrigo Company plc (PRGO) Q1 2023 Earnings Call Transcript

The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Perrigo (PRGO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023.

Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View

HRA Pharma asked the Food and Drug Administration to allow over-the-counter sales of Opill after the Supreme Court said there was no federal right to abortion.

FDA may allow birth control pill without prescription this summer as experts weigh data

Perrigo (PRGO) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.33 per share a year ago.

Perrigo (PRGO) Q1 Earnings and Revenues Top Estimates

DUBLIN , May 9, 2023 /PRNewswire/ --  First Quarter 2023 Highlights: First quarter net sales grew 10.0% versus the prior year quarter to $1.2 billion. Constant currency net sales(1) increased 13.0% and organic(2) net sales grew 6.4% compared to the prior year quarter.

Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations

DUBLIN , May 9, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Murray S. Kessler has notified the Company of his intent to retire as President and Chief Executive Officer, with a target effective date of July 31, 2023.

Perrigo Announces Chief Executive Officer Retirement and Succession Plan

DUBLIN , April 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2023 results on Tuesday, May 9, 2023. The Company will also host a conference call beginning at 8:30 A.M.

Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023

Brand Partners with TerraCycle® to Offer Consumers Way to Recycle Product Waste CHICAGO, April 6, 2023 /PRNewswire/ -- Firefly®, a leading provider in children's oral care solutions, is taking action to reduce the amount of waste making its way into landfills. In partnership with international recycling leader TerraCycle, Firefly is offering consumers in the contiguous United States a way to responsibly recycle waste from their products.

Firefly® Expands Its Commitment to Sustainability with Free Recycling Program

DUBLIN , March 28, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that the U.S. Food and Drug Administration (FDA) has rescheduled a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) for May 9 & 10, 2023, to review the Company's application for Opill® daily oral contraceptive for over-the-counter (OTC) use. Perrigo announced in July 2022 that its HRA Pharma affiliate filed an application with the FDA for the Rx-to-OTC switch of Opill®, a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill).

Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use

Perrigo says the decision affects certain lots of Gerber Good Start SoothePro powdered variety that was made at its plant in Eau Claire, Wis.

Some Gerber Baby Formula Recalled Due to Possible Contamination

Assured Guaranty

Blackrock Inc

BWX Technologies

Commerce Bancshares

Cogent Communications Holdings

Canadian National Railway Company

eBay

Elevance Health Inc

Equinix

Evans Bancorp

Exponent

Comfort Systems USA

Genpact

Gaming and Leisure Properties

Home Depot

Jack Henry & Associates

Kforce

Kimberly-Clark

L3Harris

LeMaitre Vascular

Louisiana-Pacific

Northrim BanCorp

Public Service Enterprise Group

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.3% and a median increase of 8.1%.

32 Upcoming Dividend Increases Including 2 Dividend Kings

DUBLIN , March 2, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO, Murray S. Kessler and CFO Eduardo Bezerra are scheduled to present at the 12th Annual UBS Global Consumer and Retail Conference in New York City on Wednesday, March 15 th at 3:00 PM EST.

Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference

DUBLIN , March 1, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter ("OTC") equivalent of Advil® Dual Action Tablets 250 mg/125 mg. The Company anticipates launching the product by Spring 2023.

Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets

Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.

Perrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales

DUBLIN , Feb. 28, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) announced that it will outline its plans to drive long-term profitable growth and build shareholder value at today's Virtual Investor Day. Several key members of the Perrigo leadership team, including President and Chief Executive Officer, Murray S.

Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day

Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Perrigo Stock (PRGO)